Switch Therapeutics

United States - San Francisco, California

• 15/03/2023
• Series A
• $52,000,000

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope.

Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.

To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.

Related People

Dee DattaCo Founder

United States - San Francisco Bay Area

Dee Datta is the Chief Executive Officer and a co-founder of Switch Therapeutics, an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs.

Prior to Switch, Dee served as Chief Business Officer at XOMA and Vice President of Corporate Development at Forty Seven Inc. Dee holds a Ph.D. in Biochemistry and Molecular Biophysics from Caltech and MBA from Stanford University.

LinkedIn https://www.linkedin.com/in/deedatta/